FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:923-924 April 4, 1996 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Meyer zum Büschenfelde, K.-H. PubMed Citation

To the Editor: Meyer zum Büschenfelde and Lohse (Oct. 12 issue)¹ suggest that patients with mild autoimmune hepatitis should be treated. However, few data support the contention that such patients will benefit. Although the results of large controlled trials support the use of corticosteroids in the treatment of autoimmune hepatitis,^2,3,4 these beneficial effects are fully established only in patients with the most severe histologic manifestations.⁵ The effects of corticosteroids in reducing mortality appeared to be confined to patients whose initial live biopsies revealed bridging necrosis, multilobular necrosis, or cirrhosis. There were no deaths among patients whose initial liver biopsies revealed . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.